Positioning Acomplia: Has the Drug Arrived Before the Disease?
Executive Summary
Sanofi-Aventis is the envy of many as it awaits approval for fat-busting metabolic syndrome drug, Acomplia. But obesity is rarely reimbursed; metabolic syndrome still undefined.
You may also be interested in...
Drug Development Prospecting: Will Sirtris' Pipeline Pay Dividends at FDA?
GlaxoSmithKline went out on a limb by paying $720 million for Sirtris' relatively untested enzyme technology. How FDA evaluates the first-in-class therapy will determine whether GSK was pound wise or pound foolish. Two former FDA reviewers weigh in on how the company can make the most from its investment.
Sanofi-Aventis' Zimulti: Knowing When to Say When
Rimonabant had all the early signs of a mega-blockbuster. But behind that shiny veneer was a drug with a serious risk profile-one that mimicked the suicidality rates of the SSRI class. That made rimonabant an enormous red flag for FDA reviewers. Why didn't Sanofi-Aventis see it coming?
Obecure Ltd.
Israel's Obecure is investigating the potential of a marketed compound, betahistine, in obesity. It's hoping this repositioning approach will both accelerate timelines and help it overcome growing drug safety hurdles.